Preparation and Characterisation of Liposomal Formulations of Levamisole and Albendazole Used in Veterinary Medicine

Abstract

The aim of this study is to by converting albendazole and levamisole, which are antiparasitic drugs used in both humans and animals, into liposomal formulations under laboratory conditions. To ascertain the circumstance in practice, characterization studies were additionally conducted. The study was performed by modifying the hydration of the thin lipid film. Experiments were carried out with egg phosphatidylcholine, cholesterol, chloroform and methanol in different amounts. Albendazole and levamisole formulations were made with the substances used in liposomes. Zeta potential, polydispersity index, encapsulation efficiency, particle size measurements and scanning electron microscopy were performed as part of characterization studies. The results show that Lipo LVM has the smallest particle size value at 380.87 ± 19.52 nm, whereas Lipo LVM–PBS has the largest particle size value at 7236.67 ± 443.89 nm. Values for the polydispersity index fall between 0.527 and 0.896. Zeta potential levels, on the other hand, range from -7.6 mV to -46.8 mV. While this value was determined as -8.2 ± 0.4 mV in LD Lipo ABZ and -18.4 ± 0.6 mV in HD Lipo ABZ, respectively. Both HD Lipo ABZ and LD Lipo ABZ have polydispersity indices for ABZ of 0.529 ± 0.066 and 0.896 ± 0.085, respectively. It was found that the particle size rose as the desired amount of liposomal albendazole increased. It was found that the liposomization of albendazole was higher than that of levamisole. Albendazole and levamisole liposomal formulations were successfully developed in the investigation. By carrying out characterization studies, it was discovered that it may be employed in clinical trials. In the upcoming years, it is anticipated that continuous research in the field of nanotechnology will improve human and animal health and aid to more effectively control parasite infestations.

Keywords

• Albendazole
• levamisole
• liposome